As of Feb 24
| +0.13 / +2.70%|
The 6 analysts offering 12-month price forecasts for Conatus Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 26.00 and a low estimate of 4.00. The median estimate represents a +81.82% increase from the last price of 4.95.
The current consensus among 6 polled investment analysts is to Buy stock in Conatus Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.